InterMune Inc (ITMN) Rises on Takeover Rumor

InterMune Inc (ITMN) Rises on Takeover Rumor
InterMune Inc ITMN

Shares of InterMune Inc (NASDAQ:ITMN) were up around 10.8% on Mar 7 to end the day’s trading at $33.87, after reports from news agencies like Reuters and CNBC claimed that the company was attracting takeover interest from several pharmaceutical giants.

Play Quizzes 4

InterMune Inc (NASDAQ:ITMN) has emerged as an attractive acquisition target after the chances of Esbriet (pirfenidone) gaining U.S. approval brightened following the announcement of encouraging top-line results from the phase III ASCEND study on the drug last month.

The ASCEND study is evaluating Esbriet in patients suffering from idiopathic pulmonary fibrosis (IPF) in the U.S. Results from the study showed that treatment with Esbriet significantly reduced IPF disease progression at week 52 thus meeting the primary objective of the study. Esbriet also demonstrated significant treatment effects in the six-minute walk test distance change and progression-free survival.

London Value Investor Conference: Joel Greenblatt On Value Investing In 2022

The first London Value Investor Conference was held in April 2012 and it has since grown to become the largest gathering of Value Investors in Europe, bringing together some of the best investors every year. At this year’s conference, held on May 19th, Simon Brewer, the former CIO of Morgan Stanley and Senior Adviser to Read More

We note that Esbriet is the only approved drug in the world for the treatment of IPF. Esbriet is approved and available in Germany, France, Italy and the UK among several other EU countries. The drug is also approved in countries like Canada, Japan, China, India, Argentina and Mexico. However, it is yet to be available for IPF patients in the U.S.

Several pharma companies have seen the worst of the patent cliff and are slowly offsetting these losses on the back of multiple initiatives. At this point of time several large pharma companies would love to have an orphan drug like Esbriet in their portfolio. Companies like Boehringer Ingelheim, Novartis (NVS) and Sanofi(SNY), which are developing candidates for IPF, may also target the maker of Esbriet.

InterMune presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector includeBiogen Idec Inc. (BIIB) carrying a Zacks Rank #1 (Strong Buy).

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

InterMune Inc (NASDAQ:ITMN): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

Updated on

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were audited and attested by Baker Tilly, an independent accounting firm.
Previous article Activists On The Rise In IT
Next article Why I Sold – Part 3

No posts to display